Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

CHEK2 mutations and the risk of papillary thyroid cancer.

Siołek M, Cybulski C, Gąsior-Perczak D, Kowalik A, Kozak-Klonowska B, Kowalska A, Chłopek M, Kluźniak W, Wokołorczyk D, Pałyga I, Walczyk A, Lizis-Kolus K, Sun P, Lubiński J, Narod SA, Góźdż S.

Int J Cancer. 2015 Aug 1;137(3):548-52. doi: 10.1002/ijc.29426. Epub 2015 Jan 28.

2.

The risk of gastric cancer in carriers of CHEK2 mutations.

Teodorczyk U, Cybulski C, Wokołorczyk D, Jakubowska A, Starzyńska T, Lawniczak M, Domagała P, Ferenc K, Marlicz K, Banaszkiewicz Z, Wiśniowski R, Narod SA, Lubiński J.

Fam Cancer. 2013 Sep;12(3):473-8. doi: 10.1007/s10689-012-9599-2.

PMID:
23296741
3.

A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland.

Bąk A, Janiszewska H, Junkiert-Czarnecka A, Heise M, Pilarska-Deltow M, Laskowski R, Pasińska M, Haus O.

Hered Cancer Clin Pract. 2014 Apr 8;12(1):10. doi: 10.1186/1897-4287-12-10.

4.

Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.

Muranen TA, Blomqvist C, Dörk T, Jakubowska A, Heikkilä P, Fagerholm R, Greco D, Aittomäki K, Bojesen SE, Shah M, Dunning AM, Rhenius V, Hall P, Czene K, Brand JS, Darabi H, Chang-Claude J, Rudolph A, Nordestgaard BG, Couch FJ, Hart SN, Figueroa J, García-Closas M, Fasching PA, Beckmann MW, Li J, Liu J, Andrulis IL, Winqvist R, Pylkäs K, Mannermaa A, Kataja V, Lindblom A, Margolin S, Lubinski J, Dubrowinskaja N, Bolla MK, Dennis J, Michailidou K, Wang Q, Easton DF, Pharoah PD, Schmidt MK, Nevanlinna H.

Breast Cancer Res. 2016 Oct 3;18(1):98.

5.

Case report of a woman with monoclonal gammapathy and papillary thyroid carcinoma, diagnosed because of detection of CHEK2 (I157T) mutation in genetic examinations.

Lizis-Kolus K, Kowalska A, Kozak-Klonowska B, Siołek M, Słuszniak J, Lubiński J, Cybulski C.

Endokrynol Pol. 2010 Sep-Oct;61(5):502-6.

PMID:
21049466
6.

Association of two mutations in the CHEK2 gene with breast cancer.

Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, Lazjuk GI, Rogov YI, Dammann O, Bremer M, Karstens JH, Sohn C, Dörk T.

Int J Cancer. 2005 Aug 20;116(2):263-6.

7.

Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.

Cybulski C, Wokołorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Masojć B, Deebniak T, Górski B, Blecharz P, Narod SA, Lubiński J.

J Clin Oncol. 2011 Oct 1;29(28):3747-52. doi: 10.1200/JCO.2010.34.0778. Epub 2011 Aug 29.

PMID:
21876083
8.

Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.

Näslund-Koch C, Nordestgaard BG, Bojesen SE.

J Clin Oncol. 2016 Apr 10;34(11):1208-16. doi: 10.1200/JCO.2015.63.3594. Epub 2016 Feb 16.

PMID:
26884562
9.

CHEK2 mutations and HNPCC-related colorectal cancer.

Suchy J, Cybulski C, Wokołorczyk D, Oszurek O, Górski B, Debniak T, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Dziuba I, Gogacz M, Wiśniowski R, Wandzel P, Banaszkiewicz Z, Kurzawski G, Kładny J, Narod SA, Lubiński J.

Int J Cancer. 2010 Jun 15;126(12):3005-9. doi: 10.1002/ijc.25003.

10.

CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.

Hallamies S, Pelttari LM, Poikonen-Saksela P, Jekunen A, Jukkola-Vuorinen A, Auvinen P, Blomqvist C, Aittomäki K, Mattson J, Nevanlinna H.

BMC Cancer. 2017 Sep 5;17(1):620. doi: 10.1186/s12885-017-3631-8.

11.

CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.

Bayram S, Topaktaş M, Akkız H, Bekar A, Akgöllü E.

Cancer Epidemiol. 2012 Oct;36(5):453-7. doi: 10.1016/j.canep.2012.03.008. Epub 2012 Apr 20.

PMID:
22521562
12.

Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.

Domagala P, Wokolorczyk D, Cybulski C, Huzarski T, Lubinski J, Domagala W.

Breast Cancer Res Treat. 2012 Apr;132(3):937-45. doi: 10.1007/s10549-011-1635-7. Epub 2011 Jun 24.

PMID:
21701879
13.

Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.

Baloch AH, Daud S, Raheem N, Luqman M, Ahmad A, Rehman A, Shuja J, Rasheed S, Ali A, Kakar N, Naseeb HK, Mengal MA, Awan MA, Wasim M, Baloch DM, Ahmad J.

Mol Biol Rep. 2014 Feb;41(2):1103-7. doi: 10.1007/s11033-013-2956-x. Epub 2014 Jan 4.

PMID:
24390236
14.

A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.

Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, Debniak T, Masojć B, Jakubowska A, van de Wetering T, Narod SA, Lubiński J.

Breast Cancer Res Treat. 2007 Mar;102(1):119-22. Epub 2006 Aug 8.

PMID:
16897426
15.

Can selenium be a modifier of cancer risk in CHEK2 mutation carriers?

Gupta S, Jaworska-Bieniek K, Lubinski J, Jakubowska A.

Mutagenesis. 2013 Nov;28(6):625-9. doi: 10.1093/mutage/get050. Epub 2013 Oct 8.

PMID:
24106007
16.

Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers.

Leedom TP, LaDuca H, McFarland R, Li S, Dolinsky JS, Chao EC.

Cancer Genet. 2016 Sep;209(9):403-407. doi: 10.1016/j.cancergen.2016.08.005. Epub 2016 Aug 15.

17.

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.

Schmidt MK, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank MA, Meijers H, Waisfisz Q, Hollestelle A, Schutte M, van den Ouweland A, Hooning M, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Arndt V, Bermisheva M, Bogdanova NV, Bolla MK, Brauch H, Brenner H, Brüning T, Burwinkel B, Chang-Claude J, Chenevix-Trench G, Couch FJ, Cox A, Cross SS, Czene K, Dunning AM, Fasching PA, Figueroa J, Fletcher O, Flyger H, Galle E, García-Closas M, Giles GG, Haeberle L, Hall P, Hillemanns P, Hopper JL, Jakubowska A, John EM, Jones M, Khusnutdinova E, Knight JA, Kosma VM, Kristensen V, Lee A, Lindblom A, Lubinski J, Mannermaa A, Margolin S, Meindl A, Milne RL, Muranen TA, Newcomb PA, Offit K, Park-Simon TW, Peto J, Pharoah PD, Robson M, Rudolph A, Sawyer EJ, Schmutzler RK, Seynaeve C, Soens J, Southey MC, Spurdle AB, Surowy H, Swerdlow A, Tollenaar RA, Tomlinson I, Trentham-Dietz A, Vachon C, Wang Q, Whittemore AS, Ziogas A, van der Kolk L, Nevanlinna H, Dörk T, Bojesen S, Easton DF.

J Clin Oncol. 2016 Aug 10;34(23):2750-60. doi: 10.1200/JCO.2016.66.5844. Epub 2016 Jun 6.

18.

Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention.

Cybulski C, Huzarski T, Byrski T, Gronwald J, Debniak T, Jakubowska A, Górski B, Wokołorczyk D, Masojć B, Narod SA, Lubiński J.

Clin Genet. 2009 Jan;75(1):72-8. doi: 10.1111/j.1399-0004.2008.01111.x. Epub 2008 Nov 17.

PMID:
19021634
19.

The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome.

Lener MR, Kashyap A, Kluźniak W, Cybulski C, Soluch A, Pietrzak S, Huzarski T, Gronwald J, Lubiński J.

Cancer Res Treat. 2017 Apr;49(2):430-436. doi: 10.4143/crt.2016.217. Epub 2016 Jul 28.

20.

Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.

Cybulski C, Górski B, Huzarski T, Byrski T, Gronwald J, Debniak T, Wokolorczyk D, Jakubowska A, Serrano-Fernández P, Dork T, Narod SA, Lubinski J.

J Med Genet. 2009 Feb;46(2):132-5. doi: 10.1136/jmg.2008.061697. Epub 2008 Oct 17.

PMID:
18930998

Supplemental Content

Support Center